SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin

Pathology and Oncology Research

Volumn 18, Issue 3, 2012, Pages 713-720

  Jin, Jong Shiaw ^a   Tsao, Tang Yi ^a   Sun, Pei Chang ^b   Yu, Cheng Ping ^b   Tzao, Ching ^c  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Colon cancer; Histone deacetylase; Histone deacetylase inhibitor; Nude mice

Indexed keywords

CYCLIN D1; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; HISTONE H3; HISTONE H4; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN P53; RAF PROTEIN; RETINOBLASTOMA PROTEIN; SURVIVIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; COLON CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR NECROSIS;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; CYCLIN D1; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; REPRESSOR PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84863939925     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9499-7     Document Type: Article

References (28)

1. Mayer RJ (2009) Targeted therapy for advanced colorectal cancermore is not always better. N Eng J Med 360:623-625
2. WilkoW, Annika R, Silvia N, Aurelia N, Ann-Christin B, Manfred D, Volker G, Boehm M, Thomas B, Carsten D (2008) Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14:1669-1677
3. Ito K, Adcock IM (2002) Histone acetylation and histone deacetylation. Mol Biotechnol 20:99-106
4. Kuo MH, Allis CD (1998) Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20:615-626
5. Kim DH, Kim M, Kwon HJ (2003) Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36:110-119
6. Marks PA, Richon VM, Breslow R, Rifkind RA (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13:477-483
7. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP (2006) Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12:5570-5577
8. Sun PC, Tzao C, Chen BH, Liu CW, Yu CP, Jin JS (2010) Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. J Biochem Sci 17:76-85
9. Jin JS, Hsieh DS, Loh SH, Chen A, Yao CW, Yen CY (2006) Increasing expression of serine protease matriptase in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod Pathol 19:447-452
10. Jin JS, Wu WY, Lin YF (2006) Higher expression of epidermal growth factor receptor is associated with extracellular matrix metalloprotease inducer in colorectal adenocarcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Dis Markers 22:309-316
11. Jung M (2001) Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 8:1505-1511
12. Lindemann RK, Gabrielli B, Johnstone RW (2004) Histonedeacetylase inhibitors for the treatment of cancer. Cell Cycle 3:779-788
13. Truchet I, Jozan S, Baron S (2008) Estrogen and antiestrogendependent regulation of breast cancer cell proliferation in multicellular spheroids: Influence of cell microenvironment. Int J Oncol 32:1033-1039
14. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51
15. Alessandro V, Cinzia V, Gessica F, Elena CC, Mirko B, Debora R, Prasun C, Chantal P, Raffaele DF, Paola G, Christian S, Stefania DM (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. PNAS 101:15064-15069
16. Wang S, Yan-Neale Y, Cai R, Alimov I, Cohen D (2006) Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle 5:1662-1668
17. Zbar AP, Kennedy PJ, Singh V (2009) Functional outcome following restorative rectal cancer surgery. Acta Chir Iugosl 56:9-16
18. Kelly WK, O'Connor OA, Krug LM (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931
19. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33:53-61
20. Bali P, Pranpat M, Swaby R (2005) Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2. Clin Cancer Res 11:6382-6389
21. Rundall BK, Denlinger CE, Jones DR (2005) Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 138:360-367
22. Takai N, Desmond JC, Kumagai T (2004) Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10:1141-1149
23. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP (2004) Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101:2760-2770
24. Altieri DC (2006) The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18:609-615
25. Noh EJ, Lim DS, Jeong G, Lee JS (2009) An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun 378:326-331
26. Kim DH, Kundu JK, Surh YJ (2011) Redox modulation of p53: mechanisms and functional significance. Mol Carcinog 50:222-234
27. Shen F, Kirmani KZ, Xiao Z, Thirlby BH, Hickey RJ, Malkas LH (2011) Nuclear protein isoforms: implications for cancer diagnosis and therapy. J Cell Biochem 112:756-760
28. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P (2011) Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 104:1440-1451